Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment

Thomas Obadia (1, 2, 3) , Narimane Nekkab (4, 1, 2, 5) , Leanne Robinson (6, 7, 8) , Chris Drakeley (9) , Ivo Mueller (1, 6, 8) , Michael White

1 Malaria : parasites et hôtes - Malaria : parasites and hosts
2 Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics
3 Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB
4 Swiss Tropical and Public Health Institute [Basel]
5 Unibas - University of Basel
6 WEHI - The Walter and Eliza Hall Institute of Medical Research
7 Burnet Institute [Melbourne, Victoria]
8 University of Melbourne
9 LSHTM - London School of Hygiene and Tropical Medicine

Background Eliminating Plasmodium vivax will require targeting the hidden liver-stage reservoir of hypnozoites. This necessitates new interventions balancing the benefit of reducing vivax transmission against the risk of over-treating some individuals with drugs which may induce haemolysis. By measuring antibodies to a panel of vivax antigens, a strategy of serological-testing-and-treatment ( Pv SeroTAT) can identify individuals with recent blood-stage infections who are likely to carry hypnozoites and target them for radical cure. This provides a potential solution to selectively treat the vivax reservoir with 8-aminoquinolines. Methods Pv SeroTAT can identify likely hypnozoite carriers with ~80% sensitivity and specificity. Diagnostic test sensitivities and specificities ranging 50–100% were incorporated into a mathematical model of vivax transmission to explore how they affect the risks and benefits of different Pv SeroTAT strategies involving hypnozoiticidal regimens. Risk was measured as the rate of overtreatment and benefit as reduction of community-level vivax transmission. Results Across a wide range of combinations of diagnostic sensitivity and specificity, Pv SeroTAT was substantially more effective than bloodstage mass screen and treat strategies and only marginally less effective than mass drug administration. The key test characteristic determining of the benefit of Pv SeroTAT strategies is diagnostic sensitivity, with higher values leading to more hypnozoite carriers effectively treated and greater reductions in vivax transmission. The key determinant of risk is diagnostic specificity: higher specificity ensures that a lower proportion of uninfected individuals are unnecessarily treated with primaquine. These relationships are maintained in both moderate and low transmission settings (qPCR prevalence 10% and 2%). Increased treatment efficacy and adherence can partially compensate for lower test performance. Multiple rounds of Pv SeroTAT with a lower performing test may lead to similar or higher reductions in vivax transmission than fewer rounds with a higher performing test, albeit with higher rate of overtreatment. Conclusions At current performance, Pv SeroTAT is predicted to be a safe and efficacious option for targeting the hypnozoite reservoir towards vivax elimination. P. vivax sero-diagnostic tests should aim for both high performance and ease of use in the field. The target product profiles informing such development should thus reflect the trade-offs between impact, overtreatment, and ease of programmatic implementation.

Keywords: Modeling; Overtreatment; Plasmodium vivax malaria; Public health interventions; Serological test-and-treat; Test development

Domains: Santé publique et épidémiologie

Thomas Obadia, Narimane Nekkab, Leanne Robinson, Chris Drakeley, Ivo Mueller, et al.. Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment. BMC Medicine, 2022, 20 (1), pp.98. ⟨10.1186/s12916-022-02285-5⟩. ⟨pasteur-03617088⟩